Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
NORTHERN CLINICS OF ISTANBUL, vol.9, no.2, pp.173-179, 2022 (ESCI, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 9 Issue: 2
- Publication Date: 2022
- Doi Number: 10.14744/nci.2021.52323
- Journal Name: NORTHERN CLINICS OF ISTANBUL
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), Directory of Open Access Journals, TR DİZİN (ULAKBİM)
- Page Numbers: pp.173-179
- Keywords: Age-related macular degeneration, hemorrhagic, ranibizumab, TISSUE-PLASMINOGEN ACTIVATOR, RETINAL-PIGMENT EPITHELIUM, SUBMACULAR HEMORRHAGE, SUBRETINAL HEMORRHAGE, CHOROIDAL NEOVASCULARIZATION, INTRAVITREAL RANIBIZUMAB, NATURAL-HISTORY, LESIONS, BEVACIZUMAB, GAS
- Hacettepe University Affiliated: Yes
Abstract
OBJECTIVE: Predominantly hemorrhage represents one of the possible manifestations of choroidal neovascularisation (CNV) in eyes with age-related macular degeneration (AMD). The purpose of this study is to evaluate the effecte of ranibizumab treatment in patients with predominantly hemorrhagic CNV secondary to AMD.